Supplementary Table. Components, mechanisms of action, and clinical indications of FDA-approved ADCs

Indications obtained from FDA package inserts. ADC = Antibody-drug conjugate; AML = acute myelogenous leukemia; ALCL = anaplastic large cell lymphoma; ALL = acute lymphoblastic leukemia; DLBCL = diffuse large B cell lymphoma; DM4 = maytansine; FDA = Food and Drug Administration; FRα = folate receptor α; HR = hormone receptor; HER2 = human epidermal growth factor receptor 2; IgG = immunoglobulin; mAb = monoclonal antibody; MF = mycosis fungoides; MMAE = monomethyl auristatin E; NSCLC = non-small-cell lung cancer; PD-(L)1 = programmed cell death protein (Ligand) 1; TF = tissue factor; TROP-2 = trophoblastic antigen 2